Saturday 17 October 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 22.2% and free cash flow fell 73.8%, each against the same quarter a year earlier.
11.87
0.24
−1.98%
Follow TRVI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
19.66 | 10.41 | 15.03 | 9.15 | 2.98 | 8.33 | 11.45 | 3.30 | 3.11 | 0.41 |
Net Debt/EBITDA |
3.83 | 2.09 | 2.47 | 3.79 | 0.70 | 0.95 | 2.14 | 0.33 | 2.77 | (1.60) |
Debt/Assets |
0.00% | 0.00% | 0.03% | 7.44% | 37.65% | 30.26% | 0.59% | 10.41% | 23.78% | 262.94% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.09 | 0.85 | 0.52 | 0.01 | 0.18 | 0.36 | (1.27) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.98 | 0.80 | 1.09 | 0.97 | 0.85 | 0.89 | 0.86 | 0.72 | 0.64 | 1.67 |
Capex/Depreciation |
(0.08) | (0.24) | (0.45) | (0.28) | 0.00 | (0.12) | (0.23) | (1.90) | (0.01) | 0.00 |
Interest Coverage |
— | (12,881.00) | (86.76) | (25.72) | (27.02) | (71.25) | (33.64) | (105.79) | (2.46) | (6.61) |
| (30.23%) | (52.59%) | (30.59%) | (46.82%) | (153.03%) | (80.07%) | 97.38% | 26.38% | 16.02% | 8.58% | |
| (28.10%) | (47.84%) | (27.37%) | (36.10%) | (79.29%) | (61.15%) | (75.87%) | (156.18%) | (81.86%) | (43.83%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (8,102.11%) | 0.00% | 0.00% |
Return on Tangible Assets |
(23.48%) | (48.36%) | (35.47%) | (26.65%) | (134.22%) | (80.26%) | (49.12%) | (406.18%) | (83.32%) | 55.97% |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(0.31) | (0.38) | (0.32) | (0.44) | (1.27) | (1.61) | (1.97) | (42.12) | (18.97) | (0.69) |
Cash per Share |
1.40 | 1.06 | 0.84 | 1.87 | 1.61 | 2.49 | 4.88 | 16.44 | 52.30 | 0.51 |
Shareholders Equity per Share |
1.36 | 0.98 | 0.83 | 1.66 | 0.75 | 1.51 | 4.65 | 14.26 | 35.10 | (1.08) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.36 | 0.98 | 0.83 | 1.66 | 0.75 | 1.51 | 4.65 | 14.26 | 35.10 | (1.08) |
Free Cash Flow |
(42.10) | (38.29) | (31.85) | (28.33) | (28.95) | (29.03) | (23.10) | (18.45) | (7.99) | (11.19) |
Working Capital |
181.91 | 98.92 | 81.72 | 109.22 | 25.23 | 40.71 | 54.35 | 6.15 | 15.04 | (12.00) |
Capital Expenditures |
(0.01) | (0.03) | (0.14) | (0.16) | — | (0.03) | (0.01) | (0.16) | (0.01) | — |
Net Current Asset Value |
181.46 | 98.17 | 80.69 | 107.06 | 16.56 | 26.42 | 54.10 | 4.55 | 14.71 | (17.43) |
| Other line items | ||||||||||
Quick Ratio |
19.31 | 10.24 | 14.25 | 8.99 | 2.89 | 8.10 | 11.13 | 2.76 | 3.10 | 0.41 |
Depreciation/Fixed assets |
0.81 | 0.94 | 1.40 | 3.31 | 12.25 | 2.66 | 0.33 | 0.56 | 156.07 | 0.80 |
Cash ROIC |
(11.33%) | (18.47%) | (19.24%) | (11.95%) | (42.32%) | (33.55%) | (20.59%) | (126.82%) | (18.98%) | (86.18%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,606.25 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.31) | (0.38) | (0.32) | (0.44) | (1.27) | (1.61) | (1.97) | (41.76) | (18.94) | (0.69) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.36) | (0.03) | 0.00 |
Average Receivables |
— | — | — | — | — | 0.41 | 0.37 | 0.12 | 0.03 | 0.03 |
Average Payables |
3.66 | 2.61 | 2.33 | 2.85 | 2.43 | 1.81 | 1.10 | 0.57 | 0.49 | 0.49 |
Average Assets |
152.17 | 100.15 | 106.21 | 80.75 | 42.80 | 53.57 | 35.26 | 16.38 | 15.32 | 15.32 |
Average Common Equity |
141.44 | 91.10 | 95.00 | 62.27 | 22.18 | 40.91 | (27.47) | (96.96) | (78.29) | (78.29) |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates